Breast Cancer

Breast cancer information can involve anatomy, changes that need attention, screening and diagnostic tests. These topics answer different questions. This overview explains the broad distinctions and the current U.S. population-screening recommendation; it does not diagnose a breast change, choose an imaging test, or provide an individualized schedule.

What breast cancer means

Breast cancer is cancer that begins in breast tissue. The breast contains ducts, lobules, connective tissue, fat and other structures. Different cancers can begin in different parts of the breast, and not every breast cancer is alike. Some terms describe where a cancer began or how it appears under examination, but those labels do not by themselves determine a person’s prognosis or what care is appropriate.

A breast lump is not automatically cancer. Many breast changes have noncancerous explanations. At the same time, cancer cannot be ruled out by how a change feels, by the absence of pain, or by the absence of a lump. A clinician can assess the change and decide whether further evaluation is appropriate.

This page gives only a broad orientation to breast cancer. It does not explain pathology subtypes, biomarkers, stage, prognosis or treatment. Those are separate clinical topics that require evidence and context not supplied by this overview.

Breast changes that merit evaluation

Possible breast changes include a new lump or thickening, a change in breast size or shape, skin dimpling or irritation, a nipple change, or fluid from the nipple that is not expected. A change in the underarm area may also need assessment. These are examples of changes to discuss with a health professional; they are not a checklist for diagnosing cancer.

Some changes are temporary, and many are related to conditions other than cancer. Whether a change needs evaluation depends on its details and a person’s circumstances. If you notice a new or concerning change, contact a qualified health professional for assessment rather than trying to identify its cause from a photograph, touch, or online description. A recent normal mammogram does not settle the cause of a new symptom.

Symptoms are different from screening eligibility. The USPSTF mammography recommendation described below addresses screening in a defined group without symptoms. A person with a new lump, nipple change or other concern is asking a diagnostic question, not simply whether the population-screening recommendation applies. The appropriate evaluation depends on the concern and cannot be selected by this page.

If a breast change is accompanied by severe or rapidly worsening symptoms, seek timely medical help for those symptoms. This does not mean cancer is the cause. The goal is to have the concern assessed in a timely way, not to wait for a screening appointment or a particular sign to appear.

Screening is different from diagnostic evaluation

Screening uses a test to look for disease in people who do not have obvious related symptoms. Diagnostic evaluation is used to assess a symptom or an abnormal finding. Mammography can be used in screening, but a mammogram performed to investigate a new change has a different purpose. A screening recommendation cannot be used to decide what test an individual symptom needs.

An abnormal screening result is not a cancer diagnosis. It may lead to additional evaluation. A screening result also cannot explain a new change that occurs later. The person’s clinician can review what the result says and whether follow-up is needed.

Population recommendations are limited to the population described by the source. Prior breast cancer, certain high-risk breast lesions, high-risk genetic markers or syndromes, and prior high-dose chest radiation at a young age are outside the USPSTF average-risk recommendation. People in those circumstances need individualized guidance from a qualified professional and evidence specific to their history. This article does not supply a separate high-risk screening protocol.

Current U.S. mammography recommendation

The U.S. Preventive Services Task Force’s final recommendation is biennial mammography, once every two years, at ages 40 through 74 within its defined average-risk population. It is population guidance for screening, not a diagnosis, a promise about benefit for every person, or a personalized instruction. It does not cover people with prior breast cancer or the other high-risk situations described above.

The recommendation applies to cisgender women and all other people assigned female at birth, including transgender men and nonbinary people. It includes people with a family history of breast cancer or dense breasts, while retaining the high-risk exclusions above. That scope should not be broadened to everyone with breast tissue or every jurisdiction. A clinician can explain how anatomy and medical history relate to the guidance; this page does not determine personal eligibility.

For people age 75 and older within that population, the USPSTF states that evidence is insufficient to assess the balance of benefits and harms of screening mammography. An insufficient-evidence statement is not a recommendation for or against screening. It means the Task Force could not reach a conclusion from the available evidence. A general article should not turn that statement into a screening direction for an individual.

The Task Force also says evidence is insufficient to determine the balance of benefits and harms of supplemental ultrasound or MRI after a negative mammogram in people with dense breasts within that population. This page does not interpret a density result or recommend additional imaging. A person with questions about a report can review it with the clinician who ordered the test.

Screening guidance may change as evidence is reviewed. When using a recommendation, check the issuing organization, its final status, publication date, age group and exclusions. Do not treat an evidence gap as a hidden instruction or extend a recommendation beyond its stated population.

Understanding follow-up without interpreting a result

A screening result may be normal, abnormal or inconclusive, but those words need to be understood in the context of the specific test and report. An abnormal result does not necessarily mean cancer; it means the screening result needs to be considered according to the appropriate clinical process. A person should not use a general article to infer what the report means or whether a biopsy or another test is needed.

Similarly, no single result should be used to dismiss a new concern. Screening has a defined purpose and limits. If a new breast change develops, it should be raised as a symptom even when the person recently had a screening test. A clinician can determine how to assess it and whether the prior result matters.

It can help to ask the clinician: Was this test performed as screening or to evaluate a symptom? What does the report say in plain language? Is any follow-up recommended, and who will arrange it? These questions support a conversation; they do not replace professional interpretation or supply a test choice.

Breast information can feel confusing because the same test may be discussed in different contexts. A screening mammogram is part of a population program; an image ordered to investigate a change belongs to a diagnostic evaluation. The distinction is about why the test is being done, not a promise about what the result will show. A clinician can explain which question is being answered and how the result relates to the person’s history.

Breast density is another term a reader may see in a report. The USPSTF evidence statement about supplemental imaging after a negative mammogram is not a personal recommendation for ultrasound or MRI. This article cannot interpret a density category, advise on additional imaging, or say how a density result changes a particular person’s care. Those questions belong in a discussion with the clinician who knows the full record.

Keep the next question in its proper lane

Breast awareness does not require interpreting every sensation or change as cancer. It means noticing a concern, understanding that symptoms and screening are different, and seeking professional evaluation when a change needs attention. Screening recommendations are specific to a population and do not diagnose symptoms. An abnormal result is not proof of cancer, and a negative result is not a universal guarantee.

For questions about screening, use current official guidance and pay attention to the exact population and evidence limits. For a symptom, abnormal finding or individual history, seek advice from a qualified health professional. This page cannot tell whether a person has breast cancer or which evaluation is right for them.